DUBLIN, Mar. 28, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/lwpmln/investigation) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering.
Tacrolimus, also named as ""FK506"" and ""FR-900506"", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade name ""Prograf"". Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It was approved by the FDA in 1994. Tacrolimus is sold in markets of several countries and regions now. In 1998, tacrolimus preparation (injection and capsule) was approved to import into China.
Since then, tacrolimus has become a first-line clinical drug to reduce organ rejection after liver and kidney transplantation in China. The sales revenue is also increasing rapidly.
For immunosuppressant is used in transplantation, a relatively special field, it requires high technical standard and large amount of investment in new compound development. The drugs available at present are thus very monopolistic, among which tacrolimus is with the most promising future and highest market value.
Since organ transplantation volume in China is only second to that of the U.S.A., a great amount of immunosuppressant is needed. The Chinese government has chosen this drug as clinical-preferred basic immunosuppressant. In recent years, the clinical application of tacrolimus continues to expand. It can treat many autoimmune diseases and is approved effective for immune diseases without specific medicine such as rheumatoid arthritis, kidney cirrhosis syndrome, atopic dermatitis and lupus. Therefore, the future is bright for medical use of tacrolimus.
Key Topics Covered:
1 Relevant Concept of Tacrolimus
2 Market Overview of Tacrolimus in China
3 Investigation on Sales Value of Tacrolimus in China, 2009-2013
4 Investigation on Market Share of Major Tacrolimus Manufacturers in China, 2009-2013
5 Investigation on Market Size of Tacrolimus by Dosage Form in China, 2009-2013
6 Reference Price of Tacrolimus in Hospital Market in China, 2013
7 Major Manufacturing Enterprises in China Tacrolimus Market, 2009-2013
8 Prospect of China Tacrolimus Market, 2014-2018
- Fujisawa (IR)
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Yamanouchi Pharmaceutical
- Sinopharm ChuanKang Pharmaceutical Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/lwpmln/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets